Member Info for Cubed

UBS, Goldman, credit agricole all recently announcing increased holdings. Custodian accounts likely on the behalf of hedge funds / long only.

That would be “you’re” you illiterate pleb.

Negative posts ? I don’t believe you’re reading the content of my posts correctly. In what way are they negative ? On the contrary, I’m very positive on this company.

Ont has consistently said over the recent years they’ll be ebitda positive next year (2027), there is no evidence to suggest this won’t be met. When you look at the numbers lately, losses are moderating (net income -143mn in 2025) forecasted to be -110mn for 2026 and -72 in 2027. The cash cushion of £255mn sees them through to profitability with ease unless operations decline.

They do not increase borrowings every year and they have net cash on the balance sheet, £214 million in fact so where is the data behind your claims ?

A nonsense post, you clearly don’t know what you’re talking about. Take many great companies today and many re-rated DURING a period of ebitda losses - Amazon, Uber inc, I could go on …

I wouldn’t say it’s heavily manipulated. It’s just chronic how it trades for a ftse 250 Uk mid cap. Only half of the share count is free floated, of which the largest 10 holders account for 60% of the free float so it’s a thin listing. Besides that, it has a very limited active following, most active institutional investors in the uk have followed since ipo and/ or they were burnt at ipo. With the company being loss making ever since, the recent apparent turnaround in fortunes still hasn’t persuaded active Uk money to back the company. I can understand why but there has been remarkable evidence shown over the last two years that this company has now turned a corner. I suspect when the masses do “click” it’ll be twice the current share price. The sell side health care specialists do “get it” with share price targets twice the current share price. If the market fails to reflect that, then an acquirer is likely to before any long term investor can benefit after acquiring it on the cheap. Such an instance would be a classic phenomenon known to the uk, failing miserably to nurture and grow their very best to become industry champions on the world stage , and instead get bought on the cheap by more capable US peers.

Fantastic interview on the company and how they company is likely to play a crucial role within health care

https://youtu.be/apmhVBhel5A?si=65-pimyScsIQ74Qw

The company is expected to generate just shy of 400mn on an enterprise value of 1.1 billion and growing at 20% top line next year . The share price at these levels is so mis priced.

More sellers than buyers

Whose Tech are they using to sequence ?

RBC have just upgraded the company and now have a 12 month price target of £3 per share

Surprised this hasn’t been appreciated by the market …

https://www.science.org/content/article/appeals-court-agrees-nih-cannot-reduce-overhead-payments-academic-institutions

ONTs Minion sequencer was featured in a bbc documentary last night which was discussing the next potential disease outbreak and how new technologies are identifying pathogens much faster. Sadly the name of the company wasn’t mentioned.

https://www.bbc.co.uk/programmes/m002jy6q

Delphi holding is Oracle Japan ( as shown via Bloomberg) so you've double accounted.

Then go ahead and short it...

Bloomberg & New York Times reporting that the US NIH has paused the cancellations of medical research grants for now.

Investec have just initiated coverage on ONT and have issued a 12month, £2 price target.

A combined £1.2mn buy mopped the intra day decline up. Each dip is getting bought here and the buyer is insensitive at these levels.

It’s astounding how resilient this has been despite the broader market turmoil. Everything seems to be getting hoovered up by Ellison and he could still acquire another 15% of the company without having to launch a bid. The more stock he attains, the more tightly controlled the free float also becomes; the top 10 shareholders will practically own it all if he gets to that level and most of them seem very long term, sticky investors.

Tariffs less worse than feared and still no announcement on NIH funding. No news is good news. I still don’t believe nih funding to the sequencing companies gets cut, they’re doing a good thing for the benefit of society.